To address these limitations, the Australian Scleroderma Interest Group (ASIG) developed an internationally recognized screening algorithm that integrates pulmonary function testing and NT-proBNP levels to enhance early detection of PAH in SSc patients.1 Although the ASIG algorithm demonstrates high sensitivity, its limited specificity may result in unnecessary right heart catheterisations (RHC).1 RV dysfunction is an established prognostic marker in PAH,4 yet accurate and reproducible assessment of RV systolic function remains challenging due to the chamber’s complex geometry. Here, NPPB is linked to pulmonary arterial hypertension.